Background: Cisplatin is an effective chemotherapeutic agent successfully used in the treatment of a wide range of tumors. Nevertheless, nephrotoxicity has restricted its clinical use. Recent studies have strongly suggested that inflammatory mechanisms may play an important role in the pathogenesis of cisplatin nephrotoxicity. Celecoxib, a selective cyclooxygenase-2 inhibitor used as anti-inflammatory, may therefore have a protective effect on cisplatin-induced renal injury. Methods: In the present study, rats were injected intraperitoneally with a single dose of cisplatin (7 mg/kg) and/or celecoxib (30 mg/kg) for 5 days. Results: Nephrotoxicity manifested biochemically by elevations in serum creatinine, blood urea nitrogen, and proteinuria, and an increase in kidney weight as a percentage of total body weight. In addition, a marked decrease in serum albumin was observed. Lipid peroxidation in the kidney was monitored by measuring the malondialdehyde level and glutathione content, which were increased and depleted, respectively. Administration of celecoxib with cisplatin attenuated cisplatin-induced changes in kidney function parameters and oxidative stress markers. Histopathological examination of the kidney confirmed these results. Conclusion: In conclusion, this study indicates that celecoxib may be a promising drug for clinical use as a nephroprotectant against cisplatin-induced nephrotoxicity.

Yao X, Panichpisal K, Kurtzman N, Nugent K: Cisplatin nephrotoxicity: a review. Am J Med Sci 2007;334:115–124.
Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL: Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther 2007;322:8–15.
McDuffie JE, Sablad M, Ma J, Snook S: Urinary parameters predictive of cisplatin-induced acute renal injury in dogs. Cytokine 2010;52:156–162.
Erdogan S, Tosyali E, Duzguner V, Kucukgul A, Aslantas O, Celik S: Cisplatin reduces Brucella melitensis-infected cell number by inducing apoptosis, oxidant and pro-inflammatory cytokine production. Res Vet Sci 2010;88:218–226.
Kuhad A, Pilkhwal S, Sharma S, Tirkey N, Chopra K: Effect of curcumin on inflammation and oxidative stress in cisplatin induced experimental nephrotoxicity. J Agric Food Chem 2007;55:10150–10155.
Kang KP, Kim DH, Jung YJ, Lee AS, Lee S, Lee SY, Jang KY, Sung MJ, Park SK, Kim W: Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation. Nephrol Dial Transplant 2009;24:3012–3020.
Tikoo K, Kumar P, Gupta J: Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats. BMC Cancer 2009;9:107.
Tufekci O, Gunes D, Ozoğul C, Kolatan E, Altun Z, Yilmaz O, Aktaş S, Erbayraktar Z, Kirkim G, Mutafoğlu K, Soylu A, Serbetçioğlu B, Güneri EA, Olgun N: Evaluation of the effect of acetyl L-carnitine on experimental cisplatin nephrotoxicity. Chemotherapy 2009;55:451–459.
Everts B, Wahrborg P, Hedner T: COX-2 specific inhibitors – the emergence of a new class of analgesic and anti-inflammatory drugs. Clin Rheumatol 2000;19:331–343.
Martin-Garcia C, Hinojosa M, Berges P, Camacho E, Garcia-Rodriguez R, Alfaya T: Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. J Investig Allergol Clin Immunol 2003;13:20–25.
Saleh S, Ain-Shoka AA, El-Demerdash E, Khalef MM: Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury. Chemotherapy 2009;55:399–406.
Liu TT, Shih KC, Kao CC, Cheng WT, Hsieh PS: Importance of cyclooxygenase 2-mediated low-grade inflammation in the development of fructose-induced insulin resistance in rats. Chin J Physiol 2009;52:65–71.
Henry RJ, Cannon DC, Winkelman JW: Clinical Chemistry, Principles and Techniques, ed 2. New York, Harper and Row, 1974, p 525.
Henry JB: Todd Sanford Davidsohn: Clinical Diagnosis and Management by Laboratory Methods, ed 16. Philadelphia, WB Saunders and Co., 1974, p 260.
Doumas BT, Watson WA, Biggs HG: Albumin standards and the measurement of serum albumin with bromocresol green. Clin Chem Acta 1971;31:87–96.
Watanabe N, Kamei S, Ohkubo A, Yamanaka M, Ohsawa S, Makino K, Tokuda K: Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. Clin Chem 1986;32:1551–1554.
Oncu M, Gultekin F, Karaöz E, Altuntas I, Delibas N: Nephrotoxicity in rats induced by chlorpryfos-ethyl and ameliorating effects of antioxidants. Hum Exp Toxicol 2002;21:223–230.
Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351–358.
Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70–77.
Ali BH, Al-Moundhri M, Eldin MT, Nemmar A, Al-Siyabi S, Annamalai K: Amelioration of cisplatin-induced nephrotoxicity in rats by tetramethylpyrazine, a major constituent of the Chinese herb Ligusticum wallichi. Exp Biol Med (Maywood) 2008;233:891–896.
Daniel WW: Hypothesis testing; in Daniel WW, Minitab Inc. (eds): Biostatistics: A Foundation for Analysis in the Health Sciences, ed 5. New York, John Wiley and Sons, 1991, p 191.
Ramesh G, Reeves WB: TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002;110:835–842.
Ramesh G, Reeves WB: Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha. Kidney Int 2004;65:490–499.
Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, Miyaji T, McLeroy P, Nibhanupudy B, Li S, Star RA: Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 2001;60:2118–2128.
al-Harbi MM, Osman AM, al-Gharably NM, al-Bekairi AM, al-Shabanah OA, Sabah DM, Raza M: Effect of desferrioxamine on cisplatin-induced nephrotoxicity in normal rats. Chemotherapy 1995;41:448–454.
Saad SY, Al-Rikabi AC: Protection effects of taurine supplementation against cisplatin-induced nephrotoxicity in rats. Chemotherapy 2002;48:42–48.
Uehara T, Watanabe H, Itoh F, Inoue S, Koshida H, Nakamura M, Yamate J, Maruyama T: Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch Toxicol 2005;79:451–460.
Ito Y, Katagiri H, Ishii K, Kakita A, Hayashi I, Majima M: Effects of selective cyclooxygenase inhibitors on ischemia/reperfusion-induced hepatic microcirculatory dysfunction in mice. Eur Surg Res 2003;35:408–416.
Huang Y, Liu J, Wang LZ, Zhang WY, Zhu XZ: Neuroprotective effects of cyclooxygenase-2 inhibitor celecoxib against toxicity of LPS-stimulated macrophages toward motor neurons. Acta Pharmcol Sin 2005;26:952–958.
Malek HA, Saleh DM: Cyclooxygenase-2 inhibitor celecoxib in a rat model of hindlimb ischemia reperfusion. Can J Physiol Pharmacol 2009;87:353–359.
El-Ghazaly MA, Nada AS, El-Hazek RM, Khayyal MT: Effect of selective COX-2 inhibitor, celecoxib on adjuvant-induced arthritis model in irradiated rats. Int J Radiat Biol 2010;86:1079–1087.
Jiang D, Zou J, Huang L, Shi Q, Zhu X, Wang G, Yang H: Efficacy of intra-articular injection of celecoxib in a rabbit model of osteoarthritis. Int J Mol Sci 2010;11:4106–4113.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.